search
Back to results

Myosuit-based Gait Training

Primary Purpose

Neurologic Gait Disorder

Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Myosuit-based gait training
Sponsored by
Rehaklinik Zihlschlacht AG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Neurologic Gait Disorder focused on measuring Exosuit, Training, Rehabilitation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • FAC score between 2 and 4
  • Intact or mildly to moderately impaired cognition: Mini Mental State Examination (MMSE) score above 17 points
  • Subject is at least 18 years old
  • A height between 150 cm and 195 cm
  • A weight between 45 to 110 kg

Exclusion Criteria:

  • Specific neurological disorders such as Parkinson's disease and Multiple sclerosis
  • Neurological patients without gait disorders
  • Unstable cardiovascular and respiratory conditions
  • Functional Reach Test < 15.24 cm
  • 10MWT not possible with the assistance of a person
  • Major musculoskeletal conditions (e.g., rheumatoid arthritis), major limited lower extremity's range of motion, orthopedic problems and/or significant lower extremity joint pain that could affect the application of the Myosuit
  • Significant lower limb contractures (knee flexion or hip flexion contracture of >10°, Varus deformity >10°, Valgus deformity >10°) that could affect the application of the Myosuit
  • Skin integrity (on surfaces that would contact the device)
  • Significant osteoporosis (bone fragility) assessed by a medical doctor
  • Pregnancy
  • Incapacity to (safely) understand and/or follow instructions (e.g., aphasia, limited knowledge of German)
  • Incapacity to understand formal consent
  • Currently participating in other (internal) interventional studies

Sites / Locations

  • Rehaklinik Zihlschlacht AGRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Study Group: Neurological inpatients with Gait disorders

Arm Description

The group participates in the study intervention (they will undergo the Myosuit-based gait training)

Outcomes

Primary Outcome Measures

Usability of the Myosuit during task specific training
The usability will be measured with the System Usability Scale (SUS). The SUS questionnaire will be completed by the participants, as well as therapists and therapy assistants. The SUS is an easy, valid and reliable tool for measuring the usability of a device. It consists of a 10-item questionnaire about the usability of a device with five response options for respondents; from strongly agree to strongly disagree. A score above 68 can be considered above average and anything below 68 is below average.
Usability of the Myosuit during task specific training
The usability will be measured with the Usefulness, Satisfaction, and Ease of use Questionnaire (USE). The USE questionnaire will be completed by the participants, as well as therapists and therapy assistants. The USE measures the subjective usability of a product or service. It is a 30-item questionnaire that examines four dimensions of usability: usability, ease of use, ease of learning, and satisfaction. a higher score indicates better usability.
Safety of the Myosuit during task specific training.
The safety will be analyzed by the risk of falling (near falls, falls and adverse events (AE)) and the change in walking speed, step length and cadence while performing the 10 Meter Walk Test (10MWT) with versus without the Myosuit.

Secondary Outcome Measures

Motivation of patients to use the Myosuit during and after their inpatient rehabilitation
The motivation will be measured by conducting an interview with the participants
Motivation of therapists to use the Myosuit as a facilitator for gait training.
The motivation will be measured by conducting an interview with the therapists
Motivation of therapy assistants to use the Myosuit as a facilitator for gait training.
The motivation will be measured by conducting an interview with the therapy assistants
Efficacy of the four-week Myosuit-based gait training on mobility
The mobility will be measured by the de Morton Mobility Index (DEMMI). The DEMMI is an assessment on an ordinal scale level, which can depict the mobility status of geriatric patients across the entire mobility spectrum by means of 15 items. It is hierarchically structured from easy to difficult. In five subcategories (bed, chair, static balance, walking, and dynamic balance) different activities are tested. Most items are rated with zero points or one point, depending on whether the activity can be performed (1) or not (0). For some items, a maximum of two points can be awarded in order to evaluate the level of support or the quantity of walking distance in a more differentiated way. The tester adds up the points to a raw score (max. 19 points) and converts this into the DEMMI score (0 to 100 points) for statistical reasons using a conversion table. In general, a higher score indicates better mobility.
Efficacy of the four-week Myosuit-based gait training on walking speed
The walking parameter walking speed will be measured by the 10-Meter Walk Test (10MWT). The 10MWT is a performance measure used to assess walking speed in meters per second over a short distance. Walking speed < 0.70 m/s is indicative of increased risk of adverse events (fall, hospitalisation, fracture, etc.). A speed <0.40 m/s indicates a household ambulator, a speed between 0.40 and 0.80 m/s indicates a limited community ambulator and speed > 0.80 m/s indicates the possibility of a community ambulator.
Efficacy of the four-week Myosuit-based gait training on walking capacity
The walking parameter walking capacity will be measured by the 6-Minute Walk Test (6MWT). The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. An increase in the walked distance indicates improvement in basic mobility.

Full Information

First Posted
July 26, 2022
Last Updated
August 9, 2022
Sponsor
Rehaklinik Zihlschlacht AG
search

1. Study Identification

Unique Protocol Identification Number
NCT05485597
Brief Title
Myosuit-based Gait Training
Official Title
Usability and Feasibility Study of Myosuit-based Gait Training for Ambulatory Neurological Patients With Gait Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2022 (Anticipated)
Primary Completion Date
November 30, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rehaklinik Zihlschlacht AG

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will investigate the safety and feasibility of over-ground training sessions with the Myosuit for the neurological inpatients of rehabilitation clinic Zihlschlacht with a gait disorder and their therapists. It will also examine the acceptability and motivation of patients and therapists to use the device for training in the clinical setting and at home or community level. Moreover, it will present first results of the training efficacy with the Myosuit in the inpatient setting on the mobility level of the International Classification of Function. The proposed trial is designed as an open-label, non-randomized interventional study
Detailed Description
Neurological disorders are the leading cause of long-term disability in adults worldwide. The activity most affected by a neurological disease is walking. Gait disorders occur in approximately 60% of patients hospitalized for a neurological disease and are the first step toward immobility and loss of independence. Not reaching the walking speed, which is necessary to walk safely outside, hinders social (re)integration and the ability to participate in society. As a result, many neurological patients with gait disorders experience a significantly reduced health-related quality of life. Soft, lightweight wearable robots appear to be good candidates for supporting physical therapy in a clinical environment and improving functional mobility in outdoor settings and as assistive devices during activities of daily living within a home-based environment. The integration of these robots into home-based rehabilitation programs could greatly contribute to increasing the patient's activity level and social interaction, which increases the health-related quality of life in chronic neurological patients. The Investigators want to integrate this new form of therapy in the rehabilitation programme from inpatient to home setting with the aim of maintaining and/or improving patients' functional ambulatory ability and enable them to perform activities of daily living more independently. This research aims to evaluate the usability of the innovative wearable robot 'the Myosuit" and the feasibility of this new form of therapy in the inpatient setting. The investigators will also measure qualitatively and quantitatively the patients' motivation to want to continue using the device for the home training and the staff's motivation to recommend the training with this device in the home setting. Furthermore, the investigators will evaluate the staff's judgment on the feasibility of recommending the Myosuit for home-training. In a time period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit.The inpatient training sessions will be started with a therapist, and if possible and as soon as possible, the patient will continue training with an assistant of therapy. Both therapists and assistants will be trained with the device before the study begins. The investigators introduce the training with assistants as an important step for transferring the inpatient training to the home setting where the relatives will assist the patients in the training with the Myosuit and they will have no background in physiotherapy as it is the case of the assistants in this study. The investigators assume that if the inpatient training is possible with therapists and subsequently with the assistants, it will be certainly feasible with the relatives. For this study, the Myosuit (MyoSwiss AG, Zurich, Switzerland) will be used. The Myosuit is CE-Marked (Conformité Européenne; in accordance with European legislation), with reference number 1910001. The Myosuit is an untethered wearable robot designed to assist the essential mobility functions across activities of daily life, such as walking, standing, sitting, making transfers or climbing stairs. The Myosuit actively supports knee and hip extension in the early- to mid-stance phase of the gait cycle and passively aids hip flexion during swing, using elastic rubber bands All the participants will be recruited from inpatients of Rehabilitation clinic Zihlschlacht by qualified (physio)therapists. The study participants will receive sufficient information about the study design and the risks and benefits of their participation. Patients have to meet defined physical requirements. To screen whether the patients meet these physical (manufacturer's recommendations) requirements, for the safety and feasibility of using the Myosuit, a clinical evaluation will be undertaken prior to the training period. In addition, to be included in the study, participants must meet the study inclusion and exclusion criteria It is planned to recruit 15 ambulatory neurological patients with gait disorder. The estimated duration is 5 months. Mainly descriptive statistics will be performed in order to analyze the obtained data. Normal distribution will be determined visually by quantile-quantile plots and numerically by Shapiro-Wilk Normality Test. Matched-paired tests will be used to examine differences in pre-test and post-test scores. Associations between paired samples will be measured by either Spearman's rho or Pearson correlation coefficient depending on normality. Effect size will be calculated in order to measure meaningful differences between pre-test and post-test scores. A two-sided p value of <0.05 is considered statistically significant. All analyses are going to be performed using IBM® SPSS® Statistics and MATLAB and Statistics Toolbox, The MathWorks, Inc., Natick, Massachusetts, United States.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neurologic Gait Disorder
Keywords
Exosuit, Training, Rehabilitation

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
The proposed trial is designed as an open-label, non-randomized interventional study.
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study Group: Neurological inpatients with Gait disorders
Arm Type
Experimental
Arm Description
The group participates in the study intervention (they will undergo the Myosuit-based gait training)
Intervention Type
Device
Intervention Name(s)
Myosuit-based gait training
Intervention Description
In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
Primary Outcome Measure Information:
Title
Usability of the Myosuit during task specific training
Description
The usability will be measured with the System Usability Scale (SUS). The SUS questionnaire will be completed by the participants, as well as therapists and therapy assistants. The SUS is an easy, valid and reliable tool for measuring the usability of a device. It consists of a 10-item questionnaire about the usability of a device with five response options for respondents; from strongly agree to strongly disagree. A score above 68 can be considered above average and anything below 68 is below average.
Time Frame
4 weeks
Title
Usability of the Myosuit during task specific training
Description
The usability will be measured with the Usefulness, Satisfaction, and Ease of use Questionnaire (USE). The USE questionnaire will be completed by the participants, as well as therapists and therapy assistants. The USE measures the subjective usability of a product or service. It is a 30-item questionnaire that examines four dimensions of usability: usability, ease of use, ease of learning, and satisfaction. a higher score indicates better usability.
Time Frame
4 weeks
Title
Safety of the Myosuit during task specific training.
Description
The safety will be analyzed by the risk of falling (near falls, falls and adverse events (AE)) and the change in walking speed, step length and cadence while performing the 10 Meter Walk Test (10MWT) with versus without the Myosuit.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Motivation of patients to use the Myosuit during and after their inpatient rehabilitation
Description
The motivation will be measured by conducting an interview with the participants
Time Frame
4 weeks
Title
Motivation of therapists to use the Myosuit as a facilitator for gait training.
Description
The motivation will be measured by conducting an interview with the therapists
Time Frame
4 weeks
Title
Motivation of therapy assistants to use the Myosuit as a facilitator for gait training.
Description
The motivation will be measured by conducting an interview with the therapy assistants
Time Frame
4 weeks
Title
Efficacy of the four-week Myosuit-based gait training on mobility
Description
The mobility will be measured by the de Morton Mobility Index (DEMMI). The DEMMI is an assessment on an ordinal scale level, which can depict the mobility status of geriatric patients across the entire mobility spectrum by means of 15 items. It is hierarchically structured from easy to difficult. In five subcategories (bed, chair, static balance, walking, and dynamic balance) different activities are tested. Most items are rated with zero points or one point, depending on whether the activity can be performed (1) or not (0). For some items, a maximum of two points can be awarded in order to evaluate the level of support or the quantity of walking distance in a more differentiated way. The tester adds up the points to a raw score (max. 19 points) and converts this into the DEMMI score (0 to 100 points) for statistical reasons using a conversion table. In general, a higher score indicates better mobility.
Time Frame
4 weeks
Title
Efficacy of the four-week Myosuit-based gait training on walking speed
Description
The walking parameter walking speed will be measured by the 10-Meter Walk Test (10MWT). The 10MWT is a performance measure used to assess walking speed in meters per second over a short distance. Walking speed < 0.70 m/s is indicative of increased risk of adverse events (fall, hospitalisation, fracture, etc.). A speed <0.40 m/s indicates a household ambulator, a speed between 0.40 and 0.80 m/s indicates a limited community ambulator and speed > 0.80 m/s indicates the possibility of a community ambulator.
Time Frame
4 weeks
Title
Efficacy of the four-week Myosuit-based gait training on walking capacity
Description
The walking parameter walking capacity will be measured by the 6-Minute Walk Test (6MWT). The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. An increase in the walked distance indicates improvement in basic mobility.
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: FAC score between 2 and 4 Intact or mildly to moderately impaired cognition: Mini Mental State Examination (MMSE) score above 17 points Subject is at least 18 years old A height between 150 cm and 195 cm A weight between 45 to 110 kg Exclusion Criteria: Specific neurological disorders such as Parkinson's disease and Multiple sclerosis Neurological patients without gait disorders Unstable cardiovascular and respiratory conditions Functional Reach Test < 15.24 cm 10MWT not possible with the assistance of a person Major musculoskeletal conditions (e.g., rheumatoid arthritis), major limited lower extremity's range of motion, orthopedic problems and/or significant lower extremity joint pain that could affect the application of the Myosuit Significant lower limb contractures (knee flexion or hip flexion contracture of >10°, Varus deformity >10°, Valgus deformity >10°) that could affect the application of the Myosuit Skin integrity (on surfaces that would contact the device) Significant osteoporosis (bone fragility) assessed by a medical doctor Pregnancy Incapacity to (safely) understand and/or follow instructions (e.g., aphasia, limited knowledge of German) Incapacity to understand formal consent Currently participating in other (internal) interventional studies
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Liliana Paredes, Dr.
Phone
+41714243730
Email
l.paredes@rehaklinik-zihlschlacht.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Carmel Tulen, Bsc.
Phone
+41714243782
Email
c.tulen@rehaklinik-zihlschlacht.ch
Facility Information:
Facility Name
Rehaklinik Zihlschlacht AG
City
Zihlschlacht-Sitterdorf
ZIP/Postal Code
8588
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liliana Paredes, Dr.
Phone
+41714243730
Email
l.paredes@rehaklinik-zihlschlacht.ch
First Name & Middle Initial & Last Name & Degree
Carmel Tulen, BSc.

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31374751
Citation
Haufe FL, Kober AM, Schmidt K, Sancho-Puchades A, Duarte JE, Wolf P, Riener R. User-driven walking assistance: first experimental results using the MyoSuit. IEEE Int Conf Rehabil Robot. 2019 Jun;2019:944-949. doi: 10.1109/ICORR.2019.8779375.
Results Reference
result
PubMed Identifier
33032627
Citation
Haufe FL, Schmidt K, Duarte JE, Wolf P, Riener R, Xiloyannis M. Activity-based training with the Myosuit: a safety and feasibility study across diverse gait disorders. J Neuroeng Rehabil. 2020 Oct 8;17(1):135. doi: 10.1186/s12984-020-00765-4.
Results Reference
result
PubMed Identifier
33356519
Citation
Wright A, Stone K, Martinelli L, Fryer S, Smith G, Lambrick D, Stoner L, Jobson S, Faulkner J. Effect of combined home-based, overground robotic-assisted gait training and usual physiotherapy on clinical functional outcomes in people with chronic stroke: A randomized controlled trial. Clin Rehabil. 2021 Jun;35(6):882-893. doi: 10.1177/0269215520984133. Epub 2020 Dec 27.
Results Reference
result
PubMed Identifier
26289955
Citation
Buesing C, Fisch G, O'Donnell M, Shahidi I, Thomas L, Mummidisetty CK, Williams KJ, Takahashi H, Rymer WZ, Jayaraman A. Effects of a wearable exoskeleton stride management assist system (SMA(R)) on spatiotemporal gait characteristics in individuals after stroke: a randomized controlled trial. J Neuroeng Rehabil. 2015 Aug 20;12:69. doi: 10.1186/s12984-015-0062-0.
Results Reference
result
PubMed Identifier
28488268
Citation
Mehrholz J, Thomas S, Werner C, Kugler J, Pohl M, Elsner B. Electromechanical-assisted training for walking after stroke. Cochrane Database Syst Rev. 2017 May 10;5(5):CD006185. doi: 10.1002/14651858.CD006185.pub4.
Results Reference
result

Learn more about this trial

Myosuit-based Gait Training

We'll reach out to this number within 24 hrs